Biased research, aggressive sales, harmful drugs
The Health Policy Exchange
MAY 20, 2013
Unfortunately, recent case studies have illustrated that FDA approval does not necessarily provide assurances of effectiveness and safety. Although a 2007 meta-analysis first sounded the alarm about rosiglitazone's cardiovascular risks, the manufacturer successfully stalled regulatory action in the U.S.
130 
Let's personalize your content